

Invitation to SynAct Pharma's interim report Q2 2023 presentation

SynAct Pharma AB (publ) ("SynAct") will publish its Q2 report for 2023 on August 4 at 07.30 CET.

The company will host a conference call and online presentation on the same day at 15.00 CET. Torbjørn Bjerke, CEO, CFO Björn Westberg and CSO Thomas Jonassen will give an update on the development progress and financial results and will include a Q&A. The presentation will be made available on the website following the event.

The webcast will be live via the link:

<https://ir.financialhearings.com/synact-pharma-q2-2023>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id=5008683>

For further information, please contact:

Torbjørn Bjerke

CEO, SynAct Pharma AB

Phone: +46 727 44 41 58

Email: TBJE@synactpharma.com

Email: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.

For more information, please visit the company's web page: www.synactpharma.com.

Attachments

[Invitation to SynAct Pharma's interim report Q2 2023 presentation](#)